
COMPLETION OF:

- (I) **PROPOSED INVESTMENT BY METRO ARC INVESTMENTS PTE. LTD. IN A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY THROUGH THE SUBSCRIPTION OF NEW PREFERENCE SHARES**
- (II) **PROPOSED RESTRUCTURING OF WHOLLY-OWNED SUBSIDIARIES**
-

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in Hyphens Pharma International Limited's announcement dated 27 May 2022 ("Announcement").

The Board of Directors ("**Board**") of the Hyphens Pharma International Limited ("**Company**", and together with its subsidiaries, the "**Group**") refers to the Announcement in relation to the Restructuring and the Subscription.

The Board is pleased to announce that the Restructuring was completed on 27 May 2022 and DocMed has completed the Subscription and the TC Subscription on 6 June 2022. Accordingly, the issued and paid-up share capital of DocMed has increased from S\$200,000 to S\$9,300,000, comprising 3,208,488 DocMed Ordinary Shares and 356,499 DocMed Preference Shares. The shareholding structure in DocMed after the completion of the Restructuring, the TC Subscription and the Subscription is as below:

Shareholder	Number of DocMed Ordinary Shares	Number of DocMed Preference Shares	Total Number of Voting Shares in DocMed	Voting Shareholding Percentage in DocMed
Company	3,200,000	-	3,200,000	89.76%
Mr Timothy Chen	8,488	-	8,488	0.24%
Investor	-	356,499	356,499	10.00%
Total	3,208,488	356,499	3,564,987	100.00%

Further, the Board wishes to announce that the Company, DocMed, Mr Timothy Chen and the Investor has entered into the SHA, on 6 June 2022, to regulate the affairs of DocMed and the respective rights of each of its shareholders. Please refer to paragraph 4.7 of the Announcement for the salient details of the SHA.

As announced in the Announcement, the dilution from the TC Subscription and the Subscription, the adoption and the implementation of the ESOP and the ESAS (and the subsequent issuance of the DocMed Ordinary Shares arising from the ESOP and the ESAS) may result in the Company's shareholding to be diluted by more than 20% and thus will be subject to the approval of the Company's shareholders at a general meeting to be convened in due course. The Company will make further announcements to update the Shareholders on any material developments.

BY ORDER OF THE BOARD

Lim See Wah
Executive Chairman and Chief Executive Officer
Date: 6 June 2022

*This announcement has been reviewed by the Sponsor, SAC Capital Private Limited (“**Sponsor**”). This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lee Khai Yinn, who can be contacted at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542, Telephone: +65 6232 3210.